D.A. Davidson & CO. acquired a new position in Bausch Health Companies Inc (NYSE:BHC) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 16,310 shares of the company’s stock, valued at approximately $419,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of BHC. NEXT Financial Group Inc bought a new stake in Bausch Health Companies during the 3rd quarter valued at approximately $101,000. Steward Partners Investment Advisory LLC bought a new stake in Bausch Health Companies during the 3rd quarter valued at approximately $106,000. Polaris Greystone Financial Group LLC bought a new stake in Bausch Health Companies during the 3rd quarter valued at approximately $107,000. Quadrant Capital Group LLC bought a new stake in Bausch Health Companies during the 3rd quarter valued at approximately $118,000. Finally, Bedel Financial Consulting Inc. bought a new stake in Bausch Health Companies during the 3rd quarter valued at approximately $129,000. 50.09% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts recently issued reports on BHC shares. JPMorgan Chase & Co. lifted their target price on Bausch Health Companies to $18.00 and gave the company an “underweight” rating in a research note on Wednesday, August 8th. Royal Bank of Canada lifted their target price on Bausch Health Companies from $25.00 to $26.00 and gave the company a “hold” rating in a research note on Wednesday, August 8th. BMO Capital Markets lifted their target price on Bausch Health Companies from $20.00 to $22.00 and gave the company a “market perform” rating in a research note on Monday, August 13th. HC Wainwright reissued a “hold” rating and set a $20.00 target price on shares of Bausch Health Companies in a research note on Friday, August 31st. Finally, ValuEngine downgraded Bausch Health Companies from a “hold” rating to a “sell” rating in a research note on Friday, September 7th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $28.18.

NYSE:BHC opened at $24.47 on Thursday. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.91 and a current ratio of 1.14. Bausch Health Companies Inc has a 1 year low of $14.44 and a 1 year high of $28.45. The company has a market capitalization of $8.56 billion, a price-to-earnings ratio of 6.19, a PEG ratio of 0.32 and a beta of -0.28.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings data on Tuesday, November 6th. The company reported $1.15 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.84 by $0.31. Bausch Health Companies had a positive return on equity of 32.19% and a negative net margin of 40.41%. The business had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.09 billion. The company’s revenue was down 3.7% on a year-over-year basis. On average, equities analysts expect that Bausch Health Companies Inc will post 3.81 earnings per share for the current fiscal year.

In other news, Director Schutter Richard U. De acquired 125,000 shares of Bausch Health Companies stock in a transaction on Thursday, September 13th. The shares were acquired at an average price of $23.96 per share, with a total value of $2,995,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Christina Ackermann sold 19,946 shares of Bausch Health Companies stock in a transaction that occurred on Tuesday, October 16th. The stock was sold at an average price of $24.98, for a total value of $498,251.08. The disclosure for this sale can be found here. In the last ninety days, insiders acquired 165,000 shares of company stock worth $3,890,700. Corporate insiders own 11.54% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “D.A. Davidson & CO. Acquires New Position in Bausch Health Companies Inc (BHC)” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/d-a-davidson-co-acquires-new-position-in-bausch-health-companies-inc-bhc/2664044.html.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

Featured Article: Earnings Per Share (EPS)

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc (NYSE:BHC).

Institutional Ownership by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.